CALD market to reach $14.72 billion by 2030

The cerebral adrenoleukodystrophy market is projected to grow from $7.54 billion in 2025 to $14.72 billion by 2030, driven by gene therapy, expanded newborn screening and rising rare-disease spending. North America led the market in 2025, while Asia-Pacific is expected to post some of the fastest growth.

Why it matters: - The CALD market is scaling quickly as gene therapy and early screening move from niche to broader clinical use. - Growing spending on rare-disease care could improve diagnosis, access to specialty treatment and support for patients with a rare, progressive neurological condition. - The market forecast points to rising commercial and research activity around a disease with limited treatment options.

What happened: - The cerebral adrenoleukodystrophy market was valued at $7.54 billion in 2025. - The market is projected to reach $8.64 billion in 2026. - The Business Research Company forecasts the market will hit $14.72 billion by 2030. - The report estimates a 14.6% compound annual growth rate from 2025 to 2026 and a 14.2% CAGR through 2030. - North America held the largest market share in 2025.

The details: - CALD is a rare, progressive neurological disorder that primarily affects males. - The condition is caused by mutations in the ABCD1 gene. - CALD leads to a buildup of very long-chain fatty acids in the brain. - That buildup damages the myelin sheath that protects nerve cells. - Symptoms include cognitive decline, behavioral changes and motor skill difficulties. - Historical growth was supported by advances in genetic understanding of adrenoleukodystrophy, more stem cell transplantation treatments, larger rare-disease registries, stronger neurologist awareness and more specialty centers. - Future growth is expected to come from wider gene therapy adoption, higher investment in rare-disease drug development, expanded newborn screening, more personalized medicine and stronger collaboration between research institutions and clinical centers. - The report cites faster uptake of gene therapy approaches, broader early diagnostic screening, greater use of stem cell transplantation, more rare-disease awareness campaigns and better supportive care management as key trends. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - Asia-Pacific and other emerging markets are expected to grow fastest as healthcare infrastructure, diagnostic capabilities and rare-disease awareness improve. - Increased healthcare spending worldwide is a major growth driver for the CALD market. - The report links that spending to aging populations, more chronic illness, medical technology advances, higher drug prices and broader health coverage. - The Centers for Medicare and Medicaid Services reported in December 2024 that U.S. national health expenditures grew 7.5% in 2023, outpacing GDP growth of 6.1%. - CMS projects U.S. national health expenditures will grow at an average annual rate of 5.6% from 2023 to 2032. - CMS also projects healthcare’s share of GDP will rise from 17.3% in 2022 to 19.7% by 2032. - The company is offering a free sample of the report and the full market report online: More information and the full report.

Between the lines: - The forecast reflects a market that is still small relative to broader healthcare categories but is expanding quickly because rare-disease treatments are becoming more specialized and more commercially viable. - North America’s lead suggests stronger access to specialty care and diagnostics today, while faster growth in Asia-Pacific signals room for market expansion as health systems improve. - The emphasis on gene therapy and newborn screening shows the market is shifting toward earlier intervention, which could change patient outcomes and treatment demand.

What's next: - Market growth is likely to track progress in gene therapy, newborn screening expansion and rare-disease drug development. - Greater diagnostic awareness and healthcare investment in emerging markets could widen treatment access over the next several years. - Supportive care and transplant-based treatment options may continue to play a role alongside newer genetic approaches.

The bottom line: - CALD is emerging as a fast-growing rare-disease market, with the strongest momentum tied to genetic medicine, early detection and higher healthcare spending.